CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 63 filers reported holding CYTOMX THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $5,215,000 | -66.2% | 2,849,707 | -50.7% | 0.14% | -57.7% |
Q1 2022 | $15,432,000 | -40.9% | 5,779,700 | -4.1% | 0.32% | -16.3% |
Q4 2021 | $26,109,000 | +266.1% | 6,029,700 | +330.4% | 0.38% | +252.8% |
Q3 2021 | $7,131,000 | -19.6% | 1,400,939 | 0.0% | 0.11% | -19.4% |
Q2 2021 | $8,868,000 | -25.2% | 1,400,939 | -8.7% | 0.13% | -27.6% |
Q1 2021 | $11,856,000 | +18.5% | 1,533,758 | +0.4% | 0.18% | +10.1% |
Q4 2020 | $10,004,000 | -1.4% | 1,527,352 | +0.1% | 0.17% | -31.1% |
Q3 2020 | $10,148,000 | -19.6% | 1,526,003 | +0.8% | 0.24% | -31.3% |
Q2 2020 | $12,616,000 | +54.2% | 1,514,476 | +42.0% | 0.36% | +0.9% |
Q1 2020 | $8,182,000 | -5.3% | 1,066,791 | +2.6% | 0.35% | +8.0% |
Q4 2019 | $8,639,000 | +18.2% | 1,039,593 | +5.0% | 0.33% | -25.1% |
Q3 2019 | $7,310,000 | -34.1% | 990,463 | +0.2% | 0.44% | -26.5% |
Q2 2019 | $11,089,000 | +6.9% | 988,319 | +2.4% | 0.59% | -16.4% |
Q1 2019 | $10,376,000 | -24.4% | 965,252 | +6.2% | 0.71% | -44.6% |
Q4 2018 | $13,720,000 | – | 908,586 | – | 1.28% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Burrage Capital Management LLC | 476,110 | $3,956,000 | 2.65% |
MPM BioImpact LLC | 855,437 | $7,109,000 | 2.52% |
Exane Asset Management | 87,876 | $730,250,000 | 0.90% |
Congress Park Capital LLC | 94,661 | $787,000 | 0.58% |
Perceptive Advisors | 3,253,923 | $27,040,000 | 0.54% |
BVF INC/IL | 766,148 | $6,367,000 | 0.48% |
RTW INVESTMENTS, LP | 1,039,593 | $8,639,000 | 0.33% |
EcoR1 Capital, LLC | 410,000 | $3,407,000 | 0.31% |
DAFNA Capital Management LLC | 100,000 | $831,000 | 0.28% |
HARBOURVEST PARTNERS LLC | 79,193 | $658,000 | 0.27% |